Cargando…
A human liver chimeric mouse model for non-alcoholic fatty liver disease
BACKGROUND & AIMS: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and a...
Autores principales: | Bissig-Choisat, Beatrice, Alves-Bezerra, Michele, Zorman, Barry, Ochsner, Scott A., Barzi, Mercedes, Legras, Xavier, Yang, Diane, Borowiak, Malgorzata, Dean, Adam M., York, Robert B., Galvan, N. Thao N., Goss, John, Lagor, William R., Moore, David D., Cohen, David E., McKenna, Neil J., Sumazin, Pavel, Bissig, Karl-Dimiter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138774/ https://www.ncbi.nlm.nih.gov/pubmed/34036256 http://dx.doi.org/10.1016/j.jhepr.2021.100281 |
Ejemplares similares
-
Erratum: A novel humanized mouse lacking murine p450 oxidoreductase for studying human drug metabolism
por: Barzi, Mercedes, et al.
Publicado: (2017) -
A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism
por: Barzi, Mercedes, et al.
Publicado: (2017) -
Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia
por: Pankowicz, Francis P., et al.
Publicado: (2016) -
A hepatitis B virus transgenic mouse model with a conditional, recombinant, episomal genome
por: Kruse, Robert L., et al.
Publicado: (2021) -
In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
por: Kruse, Robert L., et al.
Publicado: (2017)